MedTrace Logo

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

NCT02260388 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2018-07-06

Study results available
· View outcomes & findings →

Summary

The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine in treating cryptogenic sensory polyneuropathy (CSPN).

Conditions

  • Cryptogenic Sensory Polyneuropathy

Interventions

DRUG

Nortriptyline

DRUG

Duloxetine

DRUG

Pregabalin

DRUG

Mexiletine

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Richard Barohn, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02260388 on ClinicalTrials.gov